Hepatitis C

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy

Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy

Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings

Here's Why Regulus Therapeutics Gained 20%

Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings

Here's Why Regulus Therapeutics Gained 20%

Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient

High Drug Prices Put Gilead Under Fire From Senate Committee